TD Cowen initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and no price target Crescent develops “best-in-class” molecules for validated oncology targets, the analyst tells investors in a research note. The firm says the company’s lead asset CR-001 is a PD-1 x VEGF bispecific with potential to advance standard of care in solid tumors such as non-small cell lung cancer, a $15B market. Proof of concept data for CR-001 is expected by the second half of 2026, “which could be a significant value inflection point,” contend TD.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO: